“Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials”, J of Skin, vol. 6, no. 6, p. s72, Nov. 2022, doi: 10.25251/skin.6.supp.72.